Kinetics of Drug Molecule Interactions with a Newly Developed Nano-Gold-Modified Spike Protein Electrochemical Receptor Sensor

Dingqiang Lu 1,2, Danyang Liu 1, Xinqian Wang 1, Yujiao Liu 1, Yixuan Liu 1, Ruijuan Ren 3 and Guangchang Pang 1,2,*

1 College of Biotechnology & Food Science, Tianjin University of Commerce, Tianjin 300134, China
2 Tianjin Key Laboratory of Food Biotechnology, Tianjin 300134, China
3 Tianjin Institute for Food Safety Inspection Technology, Tianjin 300134, China
* Correspondence: pgc@tjcu.edu.cn

Abstract: In March 2020, the World Health Organization (WHO) declared COVID-19 a pandemic, and the spike protein has been reported to be an important drug target for anti-COVID-19 treatment. As such, in this study, we successfully developed a novel electrochemical receptor biosensor by immobilizing the SARS-CoV-2 spike protein and using AuNPs-HRP as an electrochemical signal amplification system. Moreover, the time-current method was used to quantify seven antiviral drug compounds, such as arbidol and chloroquine diphosphate. The results show that the spike protein and the drugs are linearly correlated within a certain concentration range and that the detection sensitivity of the sensor is extremely high. In the low concentration range of linear response, the kinetics of receptor–ligand interactions are similar to that of an enzymatic reaction. Among the investigated drug molecules, bromhexine exhibits the smallest Ka value, and thus, is most sensitively detected by the sensor. Hydroxychloroquine exhibits the largest Ka value. Molecular docking simulations of the spike protein with six small-molecule drugs show that residues of this protein, such as Asp, Trp, Asn, and Gln, form hydrogen bonds with the -OH or -NH$_2$ groups on the branched chains of small-molecule drugs. The electrochemical receptor biosensor can directly quantify the interaction between the spike protein and drugs such as abidor and hydroxychloroquine and perform kinetic studies with a limit of detection $3.3 \times 10^{-20}$ mol/L, which provides a new research method and idea for receptor–ligand interactions and pharmacodynamic evaluation.

Keywords: SARS-CoV-2; spike protein; electrochemical receptor biosensor; linkage allostery

1. Introduction

In 2019, a novel coronavirus pneumonia (coronavirus disease 19, COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, and this disease continues to be a global healthcare problem [1,2]. On 11 March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic [3], and as of 22 June 2022, more than 537,591,664 confirmed cases and 6,319,395 deaths associated with this disease have been reported worldwide [4]. The main clinical symptom of COVID-19 is fever, with most patients presenting moderate or high fever (>38.0 °C), and a small number presenting low fever (37.3–38.0 °C). Other symptoms include fatigue, dry cough, dyspnea, and asthma [5]. SARS-CoV-2 binds to the membrane protein of angiotensin converting enzyme 2 (ACE2) on the surface of lung epithelial cells through the spike protein on its surface [6]. Upon initiation by transmembrane protein serine 2 (TMPRSS2), the virus enters the host cell via subsequent interactions of different subunits and structural domains of the spike protein [7]. Moreover, new virus particles are synthesized via chemical reactions using the cell’s own amino acids, and lipid molecules [8]. These particles are released outside the cell and infect the surrounding normal cells in the same way, thus resulting
in many cells being infected by the virus [9]. When the host’s immune system detects the foreign pathogen, it becomes activated, and a large number of immune cells enter the lung tissue, thus releasing cytokines and creating a cytokine storm that attacks the infected cells. This can eventually lead to pneumonia and even to acute respiratory distress syndrome.

Receptors are a class of special proteins present in the cell membrane or within the cell. They amplify and transmit received signals to the cell interior to induce biological effects. The signals are received via a molecular recognition process that implicates the binding of ligand-cell-secreted chemicals that regulate the physiological activities of specific target cells to the receptors. The binding of ligands to receptors is mediated by hydrogen bonding, ionic bonding, and van der Waals interactions. Research on receptor–ligand interactions mainly focuses on the binding between the receptor extracellular domain and the ligand binding [10,11], which is of great importance for drug screening. To date, screening methods for anti-SARS-CoV-2 drugs include high-throughput screening [12,13], molecular dynamics simulations [14,15], and biosensors [16,17]. Naveen Vankadari [18] used molecular docking simulation to confirm that the SARS-CoV-2 spike protein is the drug target of arbidol. To prevent the virus shell from contacting, adhering, and fusing to the cell membrane of the host cell, arbidol binds to hemagglutinin (HA), the main glycoprotein on the cell surface.

Gold-soluble nanoparticles with many active centers on the surface can retain their biological activity and good electrochemical properties after adsorption of biological macromolecules, and are widely used in the immobilization of bioactive molecules [19]. After assembling sulfur cordial and AuNPs-HRP on glassy carbon electrode (GCE), the nanomaterials and enzyme reaction system undergo a series of redox reactions with $\text{H}_2\text{O}_2$ to convert the weak electrical signal into a strong electrical signal [20]. Horseradish peroxidase, the most common member of peroxidases, can catalyze $\text{H}_2\text{O}_2$ efficiently and is widely used in the field of biosensors [21]. In this study, a new receptor sensor was successfully developed by immobilizing the spike protein and using AuNPs-HRP as the signal amplification system. The interactions of the immobilized spike protein with Shuanghuangliang oral solution, arbidol, chloroquine diphosphate, lopinavir, ribavirin, bromhexine, and hydroxychloroquine sulfate were quantitatively analyzed, and the efficiency and kinetics of receptor–ligand binding were assessed.

2. Materials and Methods

2.1. Materials and Instruments

Spike protein, arbidol, chloroquine diphosphate, hydroxychloroquine sulfate, ribavirin, bromhexine, horseradish peroxidase (HRP), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (Shanghai) Trading Co, Ltd. (Shanghai, China), and Shuanghuanglian oral liquid was obtained from Harbin Pharmaceutical Group Sanjinqing Pharmaceutical Company Limited (Harbin, China). Sodium citrate and chlorauric acid were purchased from Tianjin Yingdaxigui Chemical Reagent Factory (Tianjin, China). $\text{NaOH}$ and $\text{H}_2\text{O}_2$ were obtained from Tianjin Jindong Tianzheng Fine Chemical Reagent Factory (Tianjin, China). Thionin and glutaric dialdehyde were obtained from Shanghai yuanye Bio-Technology Company Limited (Shanghai, China). Acetic acid and chitosan were purchased from Guangzhou Haoying Chemical Technology Company (Guangzhou, China). All reagents used herein were of analytical grade, and ultrapure water was used in all experiments.

The CHI 660E electrochemical workstation and three-electrode system (glassy carbon electrodes (GCE, $\Phi = 3 \text{ mm}$): Ag/AgCl reference electrode and platinum wire (Pt) counter electrode) were bought from Shanghai Chenhua Instrument Co., Ltd. (Shanghai, China), whereas the Millipore Milli-Q Pure Water System was provided by Shanghai Yarong Biochemical Equipment Co., Ltd. (Shanghai, China). The Tecnai G2F20 transmission electron microscopy (TEM) was purchased from Philips and was used for the characterization of gold nanoparticles using 200 KV of acceleration voltage. The Dimension 3100 atomic force microscope (AFM) from Veeco (Plainview, NY, USA) and the Quanta FEG 250 scanning elec-
tron microscopy (SEM) from FEI (Hillsboro, OR, USA) were used for the characterization of the sensor assembly process.

2.2. Experimental Method
2.2.1. Pretreatment and Electrochemical Characterization of Glassy Carbon Electrodes

The glassy carbon electrodes were polished with α-Al₂O₃ slurries of different sizes (1.0 µm, 0.3 µm, 0.05 µm) on chamois in sequence, and washed in an ultrasonic water bath for 30 s after each polishing, repeated 2–3 times, and then the glassy carbon electrodes were cleaned with ultrapure water. The glassy carbon electrodes were activated by cyclic voltammetry in 1 mol/L H₂SO₄ solution, and the scanning range of voltage during activation was −1.0–1.0 V, and the scanning rate was 100 mV/s. The scanning was repeated until a stable cyclic voltammetry curve appeared.

The activated glassy carbon electrode was placed in 1 × 10⁻³ mol/L K₃Fe(CN)₆ solution (containing 0.20 mol/L KNO₃) for cyclic voltammetry curve scanning with a voltage scan range of −0.1–0.6 V and a scan rate of 50 mV/s.

2.2.2. Preparation of the S Protein Receptor Sensor
1. Five µL of sulfur Thi-Chit compound solution was added to 2.5 mL of 2% chitosan solution (the chitosan solution used 2 g of chitosan dissolved in 100 mL of 1% volume acetic acid solution). This was stirred until completely dissolved to 0.32 mL of 10% glutaraldehyde solution, mixed well by blowing, then 0.2 mL of 0.01 M thionin solution was added, and finally a 2% volume of acetic acid solution was added to make a total volume of 6 mL. This was mixed well and then the solution was ready to use. The solution was dropcast on the working electrode surface. After drying in the ultra-clean bench, the cyclic voltammetry curve was measured. Then, the electrode was immersed in 0.5 mol/L NaOH solution for 5 min, removed and rinsed three times with ultrapure water, and placed in ultrapure water for 0.5 h after cleaning.

2. The above electrode was dried and self-assembled in nano gold–horseradish peroxidase solution (1 mL of gold nanosol [18] was mixed with 1 mL of 2.0 g/L horseradish peroxidase, stirred for 2 h with a magnetic stirrer and allowed to stand for 12 h at 4°C before use) at 4°C for 24 h; its cyclic voltammetry curves were measured after assembly, and the characterization of gold nanoparticles is provided in the attached document.

3. After washing the electrode surface with ultrapure water, the S protein solution was added dropwise on the electrode surface and self-assembled at 4°C for 24 h. The cyclic voltammetry curve was measured after assembling.

4. The electrode was removed and washed with ultrapure water, finally coated with BSA solution (0.5 g/100 mL) and incubated for 1 h at 37°C to close the non-specific sites, and their cyclic voltammetry curve was measured. The nano-gold-modified receptor spike protein electrochemical biosensor was obtained, and the assembly process is shown in Figure 1: Characterization of electrode surface morphology during electrode assembly using SEM.

The above steps were performed in 1 × 10⁻³ mol/L K₃Fe(CN)₆ (containing 0.20 mol/L KNO₃) solution by cyclic voltammetry with a scanning potential range of −0.1 to 0.6 V and a scanning rate of 50 mV/s, using a three-electrode system; the prepared S protein receptor sensor was used as the working electrode, the Ag/AgCl electrode as the reference electrode, and the platinum wire electrode as the counter electrode. After assembling thi and HRP on GCE, redox reaction occurs with H₂O₂: (1): H₂O₂ + HRP → Compound I + H₂O; (2): Compound I + thi (red) → Compound II + thi (ox)*; (3): Compound II + thi (ox)* + 2H⁺ → HRP + thi (ox) + H₂O; (4): thi (ox) + 2e⁻ +2H⁺ → thi (red).
2.2.3. Assessment of the Interaction of the S Protein Receptor Sensor with Related Drugs

Using a three-electrode system, the prepared spike protein receptor sensor was used as the working electrode, the Ag/AgCl electrode as the reference electrode, and the platinum wire as the counter electrodes, ultrapure water was used as the blank control, and the response currents of different concentrations of arbidol, hydroxychloroquine, and other related drugs were measured by time amperometry at a certain voltage. The rate of change of response currents was used as the detection index ($H_2O_2$ was added in advance to reach a final concentration of 8 mmol/L), and calculated according to the following equation:

$$\Delta I = \frac{I_1 - I_2}{I_1}$$

Here, $I_1$ and $I_2$ represent the pre- and post-measurement values of steady-state current at the same time points as the response current of the related drugs, respectively.

2.2.4. Simulation of Molecular Docking of the Spike Protein with Six Ligands

The crystal structure of the SARS-CoV-2 spike protein was obtained from the PDB protein and the UniProt protein databases, while the structures of the six ligands were acquired from PubChem.

The receptor protein and ligands were processed before molecular docking simulations. First, water molecules and other residue ligands of the S protein were removed using PyMOL. Then, hydrogen atoms (molecular docking acceptors) were added to the six ligands to obtain the molecular docking ligand. Finally, torsion bonds on the ligands were detected.

Simulations of the molecular docking of the spike protein and six ligands were performed using the AutoDock Vina software (Ver. 1.2.3.). This software continuously adjusts the conformation of the ligand molecule (including its orientation, position, and energy) within the Gridbox range and scores the ligand’s different conformations. During the docking process, each of the six ligands produced nine docking conformations that were then ranked from high to low, based on affinity values. The conformation with the highest

![Figure 1. Schematic illustration of the fabrication process of the spike protein receptor biosensor.](image-url)
affinity value achieves the best geometric and energy matching with the receptor protein. Subsequently, the binding modes and interactions of the spike protein with the six ligands were analyzed using PyMol and ligPlus.

3. Results

3.1. Electrochemical Characterization of Spike Protein Receptor Sensors

Cyclic voltammetry was used to characterize the electrode assembly at each stage in the preparation process, and the modification of biomolecules on the electrode surface was roughly judged based on the size of the redox peaks in the cyclic voltammogram.

As shown in Figure 2a, cyclic voltammetry was performed in $1 \times 10^{-3}$ mol/L $K_3Fe(CN)_6$ (containing 0.20 mol/L $KNO_3$) solution. After the pretreated electrode surface (curve a) was dropwise added with thionine-chitosan (curve b), the peak current increased rapidly, which was due to the good electron transfer ability of thionine, indicating that the thionine–chitosan composite film was successfully assembled to the electrode surface. Figure 2b shows our previous study [19]; curve one is the cyclic voltammogram of Thi-Chit/GCE and curve two is the cyclic voltammetry of Chit/GCE, both with $1 \times 10^{-3}$ mol/L $K_3Fe(CN)_6$ solution containing 0.20 mol/L $KNO_3$ as the test substrate (scan range 0.6 to −0.1 V, scan rate 50 mV/s). It can be seen from the figure that the peak current of the Thi-Chit/GCE electrode is significantly larger than that of the Chit/GCE electrode, and the peak current increases gradually when thi is present, indicating that thi facilitates the transfer of electrons between the electrode and the substrate. The curve corresponding to the nano-gold–horseradish peroxidase composite membrane (curve c) exhibits a higher redox peak current than the curve corresponding to thionine–chitosan due to the high electron density and dielectric properties of nano gold. These properties improve the electron transfer efficiency of the material, and this effect exceeds the hindering effect of horseradish peroxidase on electron transport. Therefore, the increased current indicates that the nano-gold–horseradish peroxidase composite membrane was successfully assembled. Compared to curve c, the redox peak current of the curve obtained after self-assembly of the spike protein receptor (curve d) is slightly reduced, probably due to the covalent binding of gold nanoparticles with the thiol-containing amino acids (methionine, cysteine) in the receptor spike protein through Au-S bonds. The presence of protein macromolecules hinders the electron transfer on the electrode surface. Finally, the redox peak current decreases upon dripping with BSA (curve e) due to the effect of this reagent in blocking the non-specific sites. Overall, the results indicate that the sensor was successfully prepared. Before use, the prepared sensor was stored in phosphate buffer at 4 °C.

The scanning electron microscope (SEM) of the sensor assembly process is shown in Figure 3. From Figure 3a, it can be seen that the surface of GCE is smooth and free of other impurities with high finish; Figure 3b is the SEM image of Thi-Chit assembled onto GCE, from which it can be seen that the surface structure of the chitosan membrane is rough and there are incompletely dissolved particles; Figure 3c shows the AuNPs-HRP/Thi-Chit/GCE and it can be seen that AuNPs-HRP is bound to the Thi-Chit membrane in a pine tree shape, which is similar to the TEM results of AuNPs-HRP; when the spike protein is assembled to the AuNPs-HRP membrane (Figure 3d), SEM shows that the spike protein has a tree-like structure, in which can be seen spherical Au particles, which is similar to the TEM results of the AuNPs-HRP/spike protein; Figure 3e shows the SEM image of BSA assembled onto the electrode, where BSA is attached to the electrode surface in a snowflake shape and tightly packed granular spherical proteins appear in different degrees.
Figure 2. (a) Cyclic voltammetry characterization of spike protein receptor sensor electrode assembly modifications. (b) the impact of thionine on electrochemical properties characterized by cyclic voltammetry; curve 1 is the cyclic voltammogram of Thi-Chit/GCE and curve 2 is the cyclic voltammogram of Chit/GCE. The peak current increases gradually when thi is present, indicating that thi facilitates the transfer of electrons between the electrode and the substrate. Cyclic voltammetry was performed in $1 \times 10^{-3}$ mol/L K$_3$Fe(CN)$_6$ (containing 0.20 mol/L KNO$_3$) solution with a scanning potential range of −0.1 to 0.6 V and a scanning rate of 50 mV/s, using a three-electrode system; the prepared S protein receptor sensor was used as the working electrode, Ag/AgCl electrode as the reference electrode and platinum wire electrode as the counter electrode.

Figure 3. SEM of sensor assembly process: (a) GCE; (b) Thi-Chit/GCE; (c) AuNPs-HRP/Thi-Chit/GCE; (d) spike protein/AuNPs-HRP/Thi-Chit/GCE; (e) BSA/spike protein/AuNPs-HRP/Thi-Chit/GCE.

3.2. Regulation of the Spike Protein Receptor Sensor and Related Drugs

In the detection of the concentration gradient of the drug to be tested, the minimum detection limit was reached when the concentrations of Shuanghuanglian oral liquid, arbidol, and lopinavir were $1 \times 10^{-20}$ mol/L, ribavirin and chloroquine diphosphate were $1 \times 10^{-19}$ mol/L, hydroxychloroquine was $1 \times 10^{-14}$ mol/L, and bromhexine was $1 \times 10^{-21}$ mol/L. Since the concentration range of the drug to be tested is wide and not easy to graph, the concentrations were redefined as follows: $pC$ is the redefined concentration of the drug to be tested, both starting from $1$, and $C$ is the initial concentration of the drug to be tested. For example, $C_{\text{Shuanghuanglian oral liquid}} = 1 \times 10^{-20}$ mol/L and...
pC_{Shuanghuanglian oral liquid} is 1, at which point pC_{Shuanghuanglian oral liquid} = 21 + \lg(C). Other drug concentrations to be measured are defined by the following equations:

\[
\begin{align*}
\text{pC}_{\text{Arbidol Hydrochloride}} &= 21 + \lg(C) \\
\text{pC}_{\text{Chloroquine diphosphate}} &= 20 + \lg(C) \\
\text{pC}_{\text{Lopinavir}} &= 21 + \lg(C) \\
\text{pC}_{\text{Ribavirin}} &= 20 + \lg(C) \\
\text{pC}_{\text{Bromhexine HCl}} &= 22 + \lg(C) \\
\text{pC}_{\text{Hydroxychloroquine Sulfate}} &= 15 + \lg(C) \\
\text{pC}_{\text{KCl}} &= 16 + \lg(C)
\end{align*}
\]

Figure 4 shows plots of the response current change rate versus the logarithmic value of the relevant drug concentration. Meanwhile, different concentrations of KCl solutions were used as blank controls.

![Figure 4](image)

**Figure 4.** Rate of change of response current in the detection range (the concentration range of Shuanghuanglian oral liquid, arbidol, and lopinavir were $1 \times 10^{-20}$ mol/L, ribavirin and chloroquine diphosphate were $1 \times 10^{-19}$ mol/L, hydroxychloroquine was $1 \times 10^{-14}$ mol/L, bromhexine was $1 \times 10^{-21}$ mol/L, and KCl was $1 \times 10^{-15}$ mol/L as control).

3.3. Kinetics of the Interaction of the Spike Protein Receptor with Different Drug Molecules

As shown in Figure 5, the rate of change of the response current increases linearly in the Shuanghuanglian oral liquid, arbidol, chloroquine diphosphate, lopinavir, ribavirin, bromhexine, and hydroxychloroquine concentration ranges of $10^{-20}$–$10^{-18}$, $10^{-20}$–$10^{-18}$, $10^{-19}$–$10^{-17}$, $10^{-19}$–$10^{-17}$, $10^{-19}$–$10^{-17}$, $10^{-21}$–$10^{-19}$, and $10^{-14}$–$10^{-12}$ mol/L, respectively. The detected concentrations were further divided within these concentration ranges, and the current change rates were plotted again as a function of drug concentrations.
The interaction between the receptor and the ligands may be described by the following equation:

\[
[R] + [L] \frac{k_1}{k_2} [RL]
\] (2)

with

\[K_d = \frac{k_2}{k_1} = \frac{[R][L]}{[RL]}\] (3)

If \([RT]\) designates the initial concentration of the receptor, then \([R] = [RT] - [RL]; \) if \([LT]\) is the total ligand concentration, then \([L] = [LT] - [RL].\) By substituting \([L]\) with \([LT] - [RL]\) and \([R]\) with \([RT] - [RL]\) in Equation (3), then the following hyperbolic quadratic equation is obtained:

\[
[RL]^2 - [RL]([RT] + [LT] + K_d) + [RT][LT] = 0
\] (4)

Equation (4) has one unknown, \([RL]\), and when \([RT]/K_d\) is fixed, \([RL]\) varies as a function of \([LT]\); it rapidly rises at the beginning, and then gradually stabilizes at a constant value. The \([RL]\) versus \([LT]\) variation curve corresponds to the saturation curve of the receptor–ligand interaction. Based on Equation (4), the binding of receptors to ligands is governed by a ligand saturation effect, similar to the “substrate saturation effect” observed for enzyme–substrate interactions.

The curves in Figure 5 were fitted by hyperbolic functions using the Origin 2018 software, and the fitted curves are presented in Figure 6.

As shown in Figure 6, in the low concentration range, the rate of current change increases with increasing drug concentration, which indicates that the receptor is not yet saturated. Beyond a certain concentration, the rate of current change remains constant or increases slightly, thus indicating that the receptor has reached saturation.
Figure 6. Fitted response curves: (A) Shuanghuanglian oral liquid $10^{-20}$-$10^{-18}$ mol/L; (B) abridol $10^{-20}$-$10^{-18}$ mol/L; (C) chloroquine diphosphate $10^{-19}$-$10^{-17}$ mol/L; (D) lopinavir $10^{-19}$-$10^{-17}$ mol/L; (E) ribavirin $10^{-19}$-$10^{-17}$ mol/L; (F) bromhexine $10^{-21}$-$10^{-19}$ mol/L; and (G) hydroxychloroquine $10^{-14}$-$10^{-12}$ mol/L (H) KCl $10^{-15}$-$10^{-13}$ mol/L as control.

By rearranging Equation (3), the following double reciprocal equation is obtained:

$$\frac{1}{[RL]} = \frac{1}{[RT]} + \frac{K_d}{[RT]} \frac{1}{[L]}$$

(5)

The plot of $1/[RL]$ as a function of $1/[L]$ yields a straight line with $K_d/[RT]$ slope, $-1/K_d$ horizontal axis intercept, and $1/[RT]$ vertical axis intercept. Figure 7 depicts the straight-line plots obtained for different drug molecules.

Figure 7. Double reciprocal plots of the fitted response curves of (A) Shuanghuanglian oral liquid $10^{-20}$-$10^{-18}$ mol/L; (B) abridol $10^{-20}$-$10^{-18}$ mol/L; (C) chloroquine diphosphate $10^{-19}$-$10^{-17}$ mol/L; (D) lopinavir $10^{-19}$-$10^{-17}$ mol/L; (E) ribavirin $10^{-19}$-$10^{-17}$ mol/L; (F) bromhexine $10^{-21}$-$10^{-19}$ mol/L; and (G) hydroxychloroquine $10^{-14}$-$10^{-12}$ mol/L.
The linear regression equations of the different drug molecules tested herein are given below:

**Shuanghuanglian oral liquid (A):**
\[
\frac{1}{\Delta I} = 0.919 \times 10^{-20} \frac{1}{C} + 1.511 \quad (R^2 = 0.988)
\]

**Abridol (B):**
\[
\frac{1}{\Delta I} = 1.957 \times 10^{-20} \frac{1}{C} + 2.408 \quad (R^2 = 0.990)
\]

**Chloroquine diphosphate (C):**
\[
\frac{1}{\Delta I} = 4.597 \times 10^{-20} \frac{1}{C} + 1.740 \quad (R^2 = 0.994)
\]

**Lopinavir (D):**
\[
\frac{1}{\Delta I} = 0.966 \times 10^{-20} \frac{1}{C} + 1.528 \quad (R^2 = 0.987)
\]

**Ribavirin (E):**
\[
\frac{1}{\Delta I} = 2.487 \times 10^{-19} \frac{1}{C} + 1.961 \quad (R^2 = 0.938)
\]

**Bromhexine (F):**
\[
\frac{1}{\Delta I} = 0.723 \times 10^{-21} \frac{1}{C} + 1.499 \quad (R^2 = 0.990)
\]

**Hydroxychloroquine (G):**
\[
\frac{1}{\Delta I} = 0.839 \times 10^{-14} \frac{1}{C} + 2.192 \quad (R^2 = 0.975)
\]

Based on the above equations, the allosteric constant Ka values corresponding to interactions with Shuanghuanglian oral liquid, arbidol, chloroquine diphosphate, lopinavir, ribavirin, bromhexine, and hydroxychloroquine are $6.083 \times 10^{-21}$, $8.140 \times 10^{-21}$, $2.644 \times 10^{-19}$, $6.325 \times 10^{-20}$, $1.270 \times 10^{-19}$, $4.823 \times 10^{-22}$, and $3.825 \times 10^{-15}$ mol/L, respectively. Notably, the allosteric constant Ka determined herein is similar to the enzymatic reaction parameter Km, which is defined as the ligand concentration at half maximum receptor biological effect. The smaller the Ka value, the higher the biological efficiency of the receptor–ligand interaction.

### 3.4. Molecular Docking Simulation Results

Affinity is an evaluation criterion for the degree of binding of the target receptor to the small-molecule ligand. The higher the absolute value of affinity, the stronger the ligand-receptor binding ability and the more stable the complex formed. The affinity values of the optimal binding conformation determined using molecular docking simulations of the spike protein with lopinavir are listed in Table 1 (see the Supplementary Materials for the remaining values). Six small-molecule drugs exhibit negative affinity values, thus indicating that the reactions of the spike protein with these molecules are spontaneous.

| Mode | Affinity (kcal/mol) | Dist From rmsd l.b. | Best Mode rmsd u.b. |
|------|---------------------|---------------------|---------------------|
| 1    | -8.9                | 0.000               | 0.000               |
| 2    | -8.7                | 3.837               | 7.715               |
| 3    | -8.5                | 3.917               | 7.819               |
| 4    | -8.2                | 3.689               | 8.673               |
| 5    | -8.1                | 3.782               | 7.807               |
| 6    | -8.1                | 21.586              | 29.164              |
| 7    | -8.0                | 14.650              | 19.782              |
| 8    | -7.8                | 3.704               | 9.997               |

When the docking affinity is $-8.9$ kcal/mol, a hydrogen bonding interaction occurs between the spike protein and lopinavir, and the RMSD of lopinavir is 2.124. The ASN394 residue interacts with lopinavir via hydrogen bonding (HB) at distances of 2.9 and 3.0 Å, and there are no π-π or π-cation interactions (Figure 8A). Based on LigPlus analysis, residues Trp69, Ala99, Leu73, Leu391, Arg393, Phe390, Asp350, Phe40, Trp349, Ala348, His378, His401, and Glu402 exhibit hydrophobic interactions (HI) with lopinavir.
When the docking affinity is $-4.7$ kcal/mol, the spike protein and chloroquine diphosphate are bound by hydrogen bonds, and the RMSD of the ligand is 2.075. The hydrogen bonding interaction of the LEU391 residue of the spike protein with chloroquine diphosphate occurs at a distance of 1.9 Å, and there are no $\pi-\pi$ or $\pi$-cation interactions between the two entities (Figure 8B). The results of LigPlus analysis demonstrate that residues Phe390, Leu73, Lys74, and Gln102 exhibit hydrophobic interactions with chloroquine diphosphate.

When the docking affinity between the spike protein and arbidol is $-5.9$ kcal/mol, the two entities interact via hydrogen bonding, and the RMSD of arbidol is 3.718. The lengths of the hydrogen bonds binding arbidol to the ASP206, TRP203, and LYS562 residues of the spike protein are 3.1, 2.1, and 3.1 Å, respectively, and no $\pi-\pi$ or $\pi$-cation interactions exist between the receptor and the ligand (Figure 8C). Residues Tyr202, Asn397, Asn394, Glu398, and Tyr196 have hydrophobic interactions with arbidol, as shown by LigPlus analysis.

Hydrogen bonding interaction between the spike protein and hydroxychloroquine sulfate occurs when the docking affinity is $-6.5$ kcal/mol. The RMSD of the ligand in this complex is 3.172. The hydrogen bonds exist between hydroxychloroquine sulfate and the TYR196, GLU208, GLN102, GLN98, and ASN210 residues of the spike protein. Their lengths are 2.4, 2.2, 3.0, 3.0, and 2.3 Å, respectively. Again, no $\pi-\pi$ or $\pi$-cation interactions exist between the receptor and the ligand (Figure 8D). Based on LigPlus analysis, residues Val209, Lys562, Gly205, and Leu95 exhibit hydrophobic interactions with hydroxychloroquine sulfate.

When the docking affinity is $-7.0$ kcal/mol, the spike protein and ribavirin interact via hydrogen bonding. The lengths of the hydrogen bonds binding ribavirin to the ALA396, GLU208, TRP566, GLN98, and ASN210 residues of the spike protein are 2.0, 2.2, 3.1, 2.1, 2.2, and 3.1 Å, respectively, and there are no $\pi-\pi$ or $\pi$-cation interactions between the receptor and the ligand (Figure 8E). The results of LigPlus analysis demonstrate that hydrophobic interactions occur between ribavirin and the Pro565, Val209, Lys562, and Leu95 residues of the spike protein.

The spike protein and bromhexine are bound by hydrogen bonds when the docking affinity between them is $-5.8$ kcal/mol. Under this condition, the RMSD of bromhexine is 2.023. The two hydrogen bonds binding the TYR385 and ASP382 residues of the spike protein to bromhexine are 2.2 Å-long, and there are no $\pi-\pi$ or $\pi$-cation interactions between the two entities (Figure 8F). Residues His401, His378, Ala348, Asp350, and Thr347 exhibit hydrophobic interactions with bromhexine, as shown by LigPlus analysis.
3.5. Molecular Docking Simulation and Ka Value

The sensing efficiency and kinetics of the spike protein sensor prepared herein were tested against seven different drugs, such as arbidol and bromohexine, at varying drug concentrations. Specifically, the allosteric constants of the drugs were determined. The results demonstrate that bromohexine has the smallest Ka value, which means that it yields the greatest change in electrochemical signal upon interacting with the receptor; thus, it is most sensitively detected. The detection sensitivity of the drugs decreases in the following order: bromohexine > Shuanghuanglian oral liquid > arbidol > lopinavir > ribavirin > chloroquine diphosphate > and hydroxychloroquine.

By analyzing the interactions between small-molecule ligands and biomacromolecular receptors, and by predicting the binding modes and affinities between the two entities, molecular docking simulations provide important information on structure-based drug design. Affinity is an evaluation criterion for the degree of binding between the target receptor and the small-molecule ligand, and the higher the affinity (absolute value), the stronger the ligand-receptor binding ability and the more stable the complex formed. As discussed in Section 3.4, the molecular docking results reveal that lopinavir exhibits the highest affinity with the prepared receptor sensor (−8.9 kcal/mol), followed by ribavirin (−7.0 kcal/mol), hydroxychloroquine (−6.5 kcal/mol), arbidol (−5.9 kcal/mol), bromohexine (−5.8 kcal/mol), and chloroquine diphosphate (−4.7 kcal/mol). Since the affinity values are all negative, the reactions of the drug molecules with the sensor are spontaneous (Table 2).

| Drug Molecule       | Chemical Structure | Ka value      | Affinity   | Residue Interactions |
|---------------------|--------------------|---------------|------------|----------------------|
| Bromohexine         | ![Bromohexine](image) | $4.823 \times 10^{-22}$ mol/L | −5.8 kcal/mol | HB: Tyr385, Asp382, His401, His378, Ala348, Asp350, Thr347 |
| Shuanghuanglian oral liquid | —                | $6.083 \times 10^{-21}$ mol/L | —          | HB: Asp206, Trp203, Lys562, Tyr202, Asn397, Asn394, Gly205, Glu398, Tyr196 |
| Arbidol             | ![Arbidol](image)  | $8.140 \times 10^{-21}$ mol/L | −5.9 kcal/mol | HB: Asn394, His399, Leu73, Leu391, Arg393, Phe390, Asp350, Phe40, Trp349, Ala348, His378, His401, Glu402 |
| Lopinavir           | ![Lopinavir](image) | $6.325 \times 10^{-20}$ mol/L | −8.9 kcal/mol | HB: Ala396, Glu208, Trp566, Gln98, Asn210, Pro565, Val209, Lys562, Leu95 |
| Ribavirin           | ![Ribavirin](image) | $1.270 \times 10^{-19}$ mol/L | −7.0 kcal/mol | HB: Ala396, Glu208, Trp566, Gln98, Asn210, Pro565, Val209, Lys562, Leu95 |
Table 2. Molecular docking simulation results and Ka values.

| Drug Molecule               | Chemical Structure | Ka value          | Affinity     | Residue Interactions |
|-----------------------------|--------------------|-------------------|--------------|----------------------|
| Chloroquine diphosphate     |                    | $2.644 \times 10^{-19}$ mol/L | $-4.7$ kcal/mol | HB: Leu391, Glu208, Gln102, Gln98, Asn210 |
| Hydroxychloroquine          |                    | $3.825 \times 10^{-15}$ mol/L | $-6.5$ kcal/mol | HB: Tyr196, Glu208, Gln102, Gln98, Asn210, Val209, Lys562, Gly205, Leu95 |

4. Discussion

Amid the COVID-19 pandemic, doctors and researchers around the world are working hard to find effective treatments and develop antiviral drugs. By preventing the SARS-CoV-2 virus from entering cells, antiviral drugs reduce the speed at which the virus spreads and replicates in the host by preventing the SARS-CoV-2 virus from entering cells. SARS-CoV-2 encodes four structural proteins including a spike glycoprotein, a membrane glycoprotein, an envelope protein, and a nucleocapsid protein [22,23], as well as non-structural proteins such as 3-chymotrypsin-like protease (3CLpro), RNA-dependent RNA polymerase (RdRp), and papain-like protease (PLpro) [24]. Nonstructural proteins, spike glycoproteins, TMPRSS2, and ACE2 are important drug targets for anti-COVID-19 treatment. In this study, spike proteins were assembled on gold nanoparticles to study their interaction with seven antiviral drugs. The kinetics of receptor–ligand binding were assessed, and the Ka values corresponding to interactions with different drug molecules were determined. The results show that bromhexine exhibits the lowest Ka value among the investigated drug molecules and thus, is most sensitively detected by the prepared sensor. Kenhinde et al. [25] investigated the inhibition mechanism of bromhexine and ambroxol hydrochlorides as blockers of the interaction of SARS-CoV-2 spike protein with ACE2 molecules and showed that bromhexine exhibited better molecular interaction and binding than ambroxol hydrochlorides with reduced affinity. This is consistent with the results of the present study in which bromoxyn had the smallest Ka value and the most sensitive sensing. In addition, Table 3 compares the research work on electrochemical sensors based on SARS-CoV-2 diagnosis of COVID-19 in the last three years. Molecular docking simulations revealed that the -NH$_2$ group of the bromhexine benzene ring forms hydrogen bonds with the -COOH and -OH groups of the Asp382 and Tyr385 residues of the spike protein, respectively. Both hydrogen bonding interactions occur at a distance of 2.2 Å. Moreover, five pairs of hydrophobic interactions exist between bromhexine and the spike protein. Bromhexine is widely used in the treatment of a series of respiratory diseases and is a selective inhibitor of transmembrane serine protease 2 [26]. In the first step of viral infection, the virion binds to the surface of the host receptor and fuses with the cell membrane. However, only the spike protein, which is activated by proteolysis, can release the fusion peptide into the target cell in a controlled manner [27], resulting in cell infection. The main hydrolase implicated in the viral infection process is TMPRSS2 [28].
Table 3. Electrochemical sensor based on SARS-CoV-2 detection with spike protein.

| Sensor Type                                      | Analyte                  | Electrode Type                  | Minimum Detection Limit | Measurement Method                         |
|--------------------------------------------------|--------------------------|---------------------------------|-------------------------|--------------------------------------------|
| electrochemical biosensor [29]                   | spike protein            | screen-printed carbon electrode| 0.3 fg/mL               | differential pulse voltammetry (DPV)       |
| surface-enhanced Raman spectroscopy (SERS) sensor [30] | spike protein RBD        | silicon nanowires               | 9.3 × 10^{-12} mol/L   | SERS spectroscopy                          |
| apasensor [31]                                   | spike protein RBD        | screen-printed carbon electrode | 66 pg/mL                | electrochemical impedance spectroscopy     |
| electrochemical biosensor [32]                   | spike protein            | glassy carbon electrode and SPCE| 1 ag/mL~10 fg/mL        | voltammetry                                |
| electrochemical biosensor [32]                   | spike protein            | carbon electrodes (DEP)         | 0.4 pg/mL for HCoV, 1.0 pg/mL for MERS-CoV | square wave voltammetry (SWV) |
| SERS-based biosensor [34]                        | SARS-CoV-2 virus in untreated saliva | silicon wafer                   | 6.07 pg/mL              | SERS spectroscopy                          |
| electrochemical biosensor combined with recombinase polymerase amplification (RPA) [35] | SARS-CoV-2               | multi-microelectrode array      | 0.972 fg/µL for RdRP gene, 3.925 fg/µL for N gene | DPV |
| a nucleic acid amplification-free electrochemical biosensor [1] | SARS-CoV-2 RNA           | SPCE                            | 5.0 ag/µL for S gene, 6.8 ag/µL for Orf gene | square-wave voltammetry (SWV) |
| molecularly imprinted polymer-based electrochemical sensor [36] | SARS-CoV-2 nucleoprotein (ncovNP) | thin film electrode             | 1.5 × 10^{-14} mol/L   | DPV |
| electrochemical receptor sensors (this study)     | spike protein            | glassy carbon electrode         | 3.3 × 10^{-20} mol/L    | cyclic voltammetry                         |

5. Conclusions

Various approaches have been reported using sensors to detect SARS-CoV-2 virus and to screen potential drugs for the treatment of COVID-19 by therapeutic target analysis, but there are no studies on the kinetics of interactions between the spike protein and antiviral drugs. The spike protein receptor sensor proposed in this study was prepared by immobilizing the spike protein as the measuring element, and then immobilizing thionine and chitosan molecules with strong conductivity and redox properties. The biocompatibility of chitosan and its abundant -NH\(^3+\) groups promotes the adsorption and fixing of gold nanoparticles that were used to adsorb the spike protein due to their large specific surface area and good electrical conductivity. Horseradish peroxidase was also incorporated into the sensor as a signal amplification system. The efficiency and kinetics of the spike protein interaction with Shuanghuanglian oral liquid, arbidol, chloroquine diphosphate, lopinavir, ribavirin, bromhexine, and hydroxychloroquine were analyzed using the time-current method (I-T method). The electrochemical receptor sensor prepared herein allows for the visualization and kinetic assessment of the interactions between the spike protein and a variety of drugs with a limit of detection 3.3 × 10^{-20} mol/L, thus providing a new and simple method for the detection of receptor–ligand interactions at a relatively low cost. In particular, this receptor sensor provides new ideas for studying receptor–ligand interactions. However, the current receptor sensors still have some shortcomings, for example, in the practical application of their characteristics, and final analytical performance in the sensor instability may lead to experimental failure, so the development of electrochemical biosensors suitable for general promotion and use that have high accuracy and stability still needs continuous efforts to promote the receptor sensors gradually towards the direction of functional diversification, miniaturization and integration, where it will show a wider range of applications in the field of disease diagnosis, genetic testing, etc.
Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/bios12100888/s1, Figure S1. (A) Spectral absorption curve of AuNPs; (B) TEM of AuNPs; (C) TEM of Thi-Chit/AuNPs-HRP; (D) TEM of AuNPs-HRP/spike protein; Figure S2. Crystal structure of spike protein and its binding site with drug molecules: (A) lopinavir, (B) chloroquine diphosphate, (C) abridol, (D) hydroxychloroquine, (E) ribavirin, (F) bromhexine; Figure S3. Three dimensional hydrogen bonding surface diagram of binding sites: (A) lopinavir, (B) chloroquine diphosphate, (C) abridol, (D) hydroxychloroquine, (E) ribavirin, (F) Bromhexine; Figure S4. Atomic force microscopy characterization of electrodes during the modification process and surface morphology parameters of electrodes at different assembly stages: a to d in the order of GCE, assembled thi-chit, assembled AuNPs-HRP, assembled spike protein; Table S1. The affinity value of the optimal spike protein/chloroquine diphosphate binding conformation; Table S2. The affinity value of the optimal spike protein/hydroxychloroquine binding conformation; Table S3. The affinity value of the optimal spike protein/ribavirin binding conformation; Table S4. The affinity value of the optimal spike protein/bromhexine binding conformation.

Author Contributions: Conceptualization, D.L. (Dingqiang Lu), G.P.; methodology, D.L. (Dingqiang Lu); formal analysis, D.L. (Dingqiang Lu); investigation, R.R.; writing-original draft preparation, D.L. (Danyang Liu), X.W., Y.L. (Yujijao Liu), Y.L. (Yixuan Liu); writing-review and editing, D.L. (Dingqiang Lu); funding acquisition, D.L. (Dingqiang Lu). All authors have read and agreed to the published version of the manuscript.

Funding: This research was financially supported by “The National Natural Science Foundation of China (31901782)”.

Data Availability Statement: This article has not been submitted to other journals, and the cited materials are labeled references.

Conflicts of Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References
1. Kashefi-Kheyrabadi, L.; Nguyen, H.V.; Go, A.; Baek, C.; Jang, N.; Lee, J.M.; Nam-Hyuk, C.; Min, J.; Min-Ho, L. Rapid, multiplexed, and nucleic acid amplification-free detection of SARS-CoV-2 RNA using an electrochemical biosensor. Biosens. Bioelectron. 2022, 195, 113649. [CrossRef] [PubMed]
2. Choudhary, S.; Silakari, O. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19. Virus Res. 2020, 287, 104618. [CrossRef] [PubMed]
3. Lim, H.; Kim, S.E.; Lee, Y.H.; Hwang, Y.H.; Kim, S.H.; Young, M.; Chung, G.T.; Kim, Y.J.; Lee, J.A. Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein. Virology 2022, 573, 118–123. [CrossRef] [PubMed]
4. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 22 June 2022).
5. Patel, T.K.; Patel, P.B.; Barvaliya, M.; Saurabh, M.K.; Bhalla, H.L.; Khosla, P.P. Efficacy and safety of lopinavir-ritonavir in 4. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 22 June 2022).
6. Velusamy, P.; Kiruba, K.; Su, C.H.; Arun, V.; Anbu, P.; Gopinath, S.C.B.; Vaseeharan, B. SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines. J. King Saud Univ. Sci. 2021, 33, 101648. [CrossRef]
7. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280.e8. [CrossRef]
8. Verma, S.; Patil, V.M.; Gupta, M.K. Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein. Drug Discov. Today 2022, 27, 103312. [CrossRef]
9. Pupovci, H.L. Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies. Biomed. Pharmacother. 2022, 153, 113368. [CrossRef]
10. Chan, W.K.B.; Zhang, Y. Virtual Screening of Human Class-A GPCRs Using Ligand Profiles Built on Multiple Ligand–Receptor Interactions. J. Mol. Biol. 2020, 432, 4872–4890. [CrossRef]
11. Zhao, Z.; Bourne, P.E. Harnessing systematic protein–ligand interaction fingerprints for drug discovery. Drug Discov. Today 2022, 27, 103319. [CrossRef]
12. Kuzikov, M.; Woens, J.; Zaliani, A.; Hambach, J.; Eden, T.; Fehse, B.; Ellinger, B.; Riecken, K. High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1. Biomed. Pharmacother. 2022, 151, 113104. [CrossRef]
13. Xu, T.; Zheng, W.; Huang, R. High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions. Drug Discov. Today 2021, 26, 2439–2444. [CrossRef]
14. Aallaei, M.; Molaakhbari, E.; Mostafavi, P.; Salarizaden, N.; Maleksah, R.E.; Afzali, D. Investigation of Cu metal nanoparticles with different morphologies to inhibit SARS-CoV-2 main protease and spike glycoprotein using Molecular Docking and Dynamics Simulation. J. Mol. Struct. 2022, 1253, 132301. [CrossRef]

15. Kumar, V.; Liu, H.; Wu, C. Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations. Comput. Biol. Med. 2021, 135, 104634. [CrossRef]

16. Zhang, Y.; Li, C.; Ke, X.; Luo, D.; Liu, Y.; Chen, Q.; Wang, H.; Song, X.; Zheng, Z. Development of a biosensor assessing SARS-CoV-2 main protease proteolytic activity in living cells for antiviral drugs screening. Virol. Sin. 2022, 37, 459–461. [CrossRef]

17. Dey-Kao, R.; Smith, G.R.; Timilsina, U.; Falls, Z.; Samudrala, R.; Stavrou, S.; Melendy, T. A fluorescence-based, gain-of-signal, live cell system to evaluate SARC-CoV-2 main protease inhibition. Antivir. Res. 2021, 195, 105183. [CrossRef]

18. Vankadari, N. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int. J. Antimicrob. Agents 2020, 56, 109998. [CrossRef]

19. Kang, X.; Pang, G.; Liang, X.; Wang, M.; Liu, J.; Zhu, W. Study on a hydrogen peroxide biosensor based on horseradish peroxidase/GNPs-thionine/chitosan. Electrochim. Acta 2019, 62, 327–334. [CrossRef]

20. Xiao, S.; Zhang, Y.; Song, P.; Xie, J.; Pang, J. The investigation of allosteric regulation mechanism of analgesic effect using SD rat taste bud tissue biosensor. Biosens. Bioelectron. 2019, 126, 815–823. [CrossRef]

21. Wang, X.; Du, L.; Liu, Y.; Wang, W.; Ren, R.; Li, M.; Pang, G. Electrochemical signal amplification strategies and their use in olfactory and taste evaluation. Biosensors 2022, 12, 566. [CrossRef]

22. Luo, L.; Qiu, Q.; Huang, F.; Liu, K.; Lan, Y.; Li, X.; Huang, Y.; Cui, L.; Luo, H. Drug repurposing against coronavirus disease 2019 (COVID-19): A review. J. Pharm. Anal. 2021, 11, 683–690. [CrossRef] [PubMed]

23. Presti, A.L.; Rezza, G.; Stefanelli, P. Selective pressure on SARS-CoV-2 protein coding genes and glycosylation site prediction. Cell 2020, 6, e00501. [CrossRef] [PubMed]

24. Semper, C.; Watanabe, N.; Savchenko, A. Structural characterization of nonstructural protein 1 from SARS-CoV-2. Cell 2021, 24, 101903. [CrossRef]

25. Kehinde, I.; Egbejimi, A.; Kaur, M. Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2. J. Mol. Graph. Model. 2022, 114, 108201. [CrossRef]

26. Habtemariam, S.; Nabavi, S.F.; Ghavami, S.; Cismaru, C.A.; Berindan-Neagoe, L.; Nabavi, S.M. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2. Microchem. J. 2021, 157, 104853. [CrossRef]

27. Millet, J.K.; Whittaker, G.R. Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015, 202, 120–134. [CrossRef]

28. Ohnishi, T.; Nakamura, T.; Shima, K.; Noguchi, K.; Chiba, N.; Matsuguchi, T. Periodontitis promotes the expression of gingival transmembrane serine protease 2 (TMPRSS2), a priming protease for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J. Oral Biol. 2022, 64, 229–236. [CrossRef]

29. Rahmati, Z.; Roushani, M.; Hosseini, H.; Choobin, H. An electrochemical immunosensor using SARS-CoV-2 spike protein-nickel hydroxide nanoparticles bio-conjugate modified SPCE for ultrasensitive detection of SARS-CoV-2 antibodies. Microchem. J. 2021, 170, 106718. [CrossRef]

30. Daoudi, K.; Ramachandran, K.; Alawadhhi, H.; Boukherrour, R.; Dogheche, E.; El Khakani, M.A.; Gaidi, M. Ultra-sensitive and fast optical detection of the spike protein of the SARS-CoV-2 using AgNPs/SiNWs nanohybrid based sensors. Surf. Interfaces 2021, 27, 101454. [CrossRef]

31. Abrego-Martinez, J.C.; Jafari, M.; Chergui, S.; Pavel, C.; Che, D.; Siaj, M. Aptamer-based electrochemical biosensor for rapid detection of SARS-CoV-2: Nanoscale electrode-aptamer-SARS-CoV-2 imaging by photo-induced force microscopy. Biosens. Bioelectron. 2022, 195, 113595. [CrossRef]

32. Liv, L.; Ćoban, G.; Nakiboglu, N. A rapid, ultrasensitive voltammetric biosensor for determining SARS-CoV-2 spike protein in real samples. Biosens. Bioelectron. 2021, 192, 113497. [CrossRef]

33. Layqah, L.; Eissa, S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Microchim Acta 2019, 186, 224–234. [CrossRef]

34. Zhang, M.; Li, X.; Pan, J.; Zhang, Y.; Zhang, L.; Wang, C.; Yan, X.; Liu, X.; Lu, G. Ultrasonic detection of SARS-CoV-2 spike protein in untreated saliva using SERS-based biosensor. Biosens. Bioelectron. 2021, 190, 113421. [CrossRef]

35. Kim, H.E.; Schuck, A.; Lee, S.H.; Lee, Y.; Kang, M.; Kim, Y.S. Sensitive electrochemical biosensor combined with isothermal amplification for point-of-care COVID-19 tests. Biosens. Bioelectron. 2021, 182, 113168. [CrossRef]

36. Raziq, A.; Kidakov, A.; Boroznjak, R.; Reut, J.; Öpik, A.; Syritski, V. Development of a portable MIP-based electrochemical sensor for detection of SARS-CoV-2 antigen. Biosens. Bioelectron. 2021, 178, 113029. [CrossRef]